[
  {
    "ts": null,
    "headline": "Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance",
    "summary": "Novartis shines with oncology growth, strong buybacks, and a $1.4B heart drug acquisition, defying headwinds like Entresto generics. Read why NVS stock is a buy.",
    "url": "https://finnhub.io/api/news?id=19544720167cb57ffae0079873d350c27432d55c7a1bc442759b979b242ebbe6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759481800,
      "headline": "Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance",
      "id": 136964031,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304608112/image_1304608112.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Novartis shines with oncology growth, strong buybacks, and a $1.4B heart drug acquisition, defying headwinds like Entresto generics. Read why NVS stock is a buy.",
      "url": "https://finnhub.io/api/news?id=19544720167cb57ffae0079873d350c27432d55c7a1bc442759b979b242ebbe6"
    }
  }
]